Product Name: Trelagliptin succinate CAS NO:1029877-94-8
Chemical & Physical Properties:
Appearance : White to off-white powder
Trelagliptin Succinate, developed by Takeda, Japan, was marketed in March 2015 under the trade name Zafatek, used for the treatment of type 2 diabetes. Troxagliptin is an ultra-long-acting dipeptidyl peptidase IV (DPP-4) inhibitor by selectively and continuously inhibiting DPP-4 to control blood sugar levels. Traxagliptin is the world’s first oral once-a-week hypoglycemic drug, and similar DPP-4 inhibitors on the market need to be taken orally once a day. Zafatek’s advantages will undoubtedly provide a more convenient treatment option for diabetic patients. , It is expected to greatly improve the convenience and compliance of patients.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.